查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808487

神经退化药物市场按类型、药物类别、剂型、作用机制、治疗方法、适应症、患者人口统计、销售管道和最终用户划分 - 2025-2030 年全球预测

Neurodegenerative Drugs Market by Type, Drug Class, Mode Of Administration, Mechanism Of Action, Therapeutic Approach, Indication, Patient Demographics, Sales Channel, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2024年神经退化药物市值将达444.9亿美元，2025年成长至477.9亿美元，复合年增长率为7.66%，2030年将达693亿美元。

主要市场统计数据
基准年2024年 444.9亿美元
预计2025年 477.9亿美元
预测年份 2030 693亿美元
复合年增长率（%） 7.66%

在前所未有的科学和政策动盪中揭示神经退化性疾病药物研究和市场开发的基本原理

全球人口老化和多因素疾病机制导致神经退化性疾病的发生，对现代医疗保健构成了最复杂的挑战之一。阿兹海默症、帕金森氏症、肌萎缩侧索硬化症和多发性硬化症等疾病正推动着人们对能够同时缓解症状和潜在疾病进展的新型治疗策略的需求。在这种迫切需求的驱动下，分子生物学、基因编辑和生物标记发现领域的突破正在重新定义药物开发的典范。

透过突破性发现和监管变化追踪神经退化疾病治疗的转变

由于科学进步和监管环境的不断演变，神经退化医学领域正在发生重大变化。精准医疗方法已经确定了新的分子标靶，从而能够开发出减缓或阻止疾病进展的治疗方法。基因治疗、单株抗体和小分子调变器的创新正在提供前所未有的干预途径。同时，主要市场的监管机构正在引入适应性许可製度和有条件核准，以应对患有衰弱性神经系统疾病的患者迫切而未得到满足的需求。

检验2025 年美国关税对神经退化药物供应链、定价结构和国际竞争力的累积影响

2025年美国关税的实施将为神经退化疾病供应链带来新的复杂性，对原料药和成品均产生影响。依赖跨境采购的製造商面临不断上升的投入成本，导致价格压力波及整个分销网络。为此，企业开始重组供应链，探索替代采购途径，并强化国内製造能力，以缓解关税带来的成本上涨。

关键市场细分洞察，有助于根据药物类别、给药方式和患者概况进行策略性定位

细緻入微地了解市场区隔对于制定神经退化药物领域的研发投资和商业化策略至关重要。按药物类型划分，品牌药和学名药的区别体现了不同的价值提案，创新品牌药价格昂贵，而学名药具有成本效益。依药物类别划分，胆碱酯酶抑制剂（如多奈哌齐、吡斯的明和Rivastigmine的明）在支持认知功能方面发挥着重要作用，而脱羧酶抑制剂（如芐丝肼、碳度巴和甲基多巴）则与多巴胺促效剂（如阿朴吗啡吗啡、卡麦角林、Pramipexole和rotigotine相辅成。免疫调节剂透过针对缓解疾病途径，为治疗开闢了新的方向。

揭示影响神经退化药物采用模式和重点区域投资重点的关键区域动态

区域动态显着影响着神经退化药物的采用和投资轨迹。在美洲，强大的研究基础设施和大量的公共和私人资金加速了尖端疗法的开发，而完善的报销框架则支持了商业性扩充性。该地区的市场参与企业利用先进的临床试验网路和上市后调查计画来检验真实世界结果并加强市场准入。

重点介绍推动神经退化性疾病治疗市场创新伙伴关係和竞争策略的产业领导者

在神经退化医学领域，一些机构以其开创性的研发和商业化方法脱颖而出。这些行业领导者正在利用多学科合作，将学术见解与内部研发能力相结合，以加速候选药物的筛选和临床前测试。他们与生物技术公司和技术供应商建立策略联盟，利用先进的分析技术和人工智慧来优化试验设计和患者招募策略。

为行业领导者制定可行的策略建议，以因应不断变化的市场和监管环境

要想在充满活力的神经退化医学领域取得成功，产业领导者必须采取多管齐下的策略方针。首先，优先投资基因疗法、生物标记主导平台和数位健康整合等前沿倡议项目，可以让企业处于创新前沿。其次，透过建立区域製造中心和达成替代采购协议来实现供应链多元化，可以降低关税波动和地缘政治变化带来的财务和营运风险。

详细了解我们强大的调查方法，它结合了多方面的资料来源、专家分析和严格的检验过程。

本研究采用全面的调查方法，旨在提供切实可行的见解和可靠的分析。本研究以广泛的二手资料研究为基础，涵盖同行评审期刊、监管备案文件和临床试验资料库，旨在了解神经退化性疾病药物研发的现状。此外，本研究也对神经科、药理学家和患者权益代表等关键意见领袖进行了初步访谈，从而对治疗需求和应用趋势提供了细緻入微的观点。

整合核心见解和策略意义，指导神经退化性疾病领域的相关人员决策

综上所述，本分析结果凸显了神经退化性疾病药物研发的变革轨迹。分子标靶和生物标记识别领域的科学突破，与加速患者用药可及性的监管创新相辅相成。同时，不断变化的关税政策和供应链动态需要企业制定适应性的商业策略，以维持成本效益和全球竞争力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 开发用于神经退化综合治疗的多标靶药物
  • 基因治疗在治疗遗传性神经退化性疾病的进展
  • 人们对重新利用现有药物治疗神经退化性疾病的兴趣日益浓厚
  • 临床试验进展揭示了新型神经退化疾病治疗的疗效
  • 将人工智慧和机器学习融入神经退化性疾病药物研发
  • 扩展针对神经发炎路径的小分子药物
  • 免疫治疗方法在神经退化性疾病治疗的影响日益扩大
  • 神经退化疾病药物血脑障壁穿透技术进展
  • 生物标记在神经退化性疾病个人化治疗发展中的作用
  • 针对神经退化性疾病中蛋白质聚集的创新药物製剂

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第八章神经退化药物市场（按类型）

  • 品牌
  • 学名药

第九章神经退化药物市场（依药物类别）

  • 胆碱酯酶抑制剂
    • 多奈哌齐
    • 吡啶斯的明
    • Rivastigmine
  • 脱羧酶抑制剂
    • 芐丝肼
    • 碳度巴
    • 甲基多巴
  • 促效剂
    • 阿扑吗啡
    • 卡麦角林
    • Pramipexole
    • rotigotine
  • 免疫调节药物

第 10 章神经退化药物市场（按剂型）

  • 注射
  • 口服
  • 经皮吸收贴片

第 11 章神经退化药物市场（依作用机制）

  • 离子通道调变器
    • 钾通道调变器
    • 钠通道调变器
  • 突触调变器

第 12 章神经退化药物市场（依治疗方法）

  • 神经保护
    • 抗发炎剂
    • 抗氧化剂
  • 预防性治疗
  • 症状治疗

第十三章神经退化药物市场（依适应症）

  • 阿兹海默症
  • 肌萎缩侧索硬化症（ALS）
  • 多发性硬化症
    • 原发性进展型
    • 復发缓解型
  • 帕金森氏症

第 14 章神经退化药物市场（依病患人口统计）

  • 成人
  • 老年人
  • 孩子们

第 15 章神经退化药物市场依销售管道

  • 离线
    • 医院药房
    • 零售药局
  • 在线的

第 16 章神经退化药物市场（依最终使用者）

  • 诊所
  • 受託研究机构
  • 医院
  • 研究所

17. 美国神经退化疾病药物市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

18. 欧洲、中东和非洲神经退化药物市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

19. 亚太神经神经退化药物市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第二十章 竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Abbott Laboratories
    • AbbVie Inc.
    • ACADIA Pharmaceuticals Inc.
    • Alpha Cognition Inc.
    • Amneal Pharmaceuticals, Inc.
    • Aquinnah Pharmaceuticals Inc.
    • Asceneuron SA
    • AstraZeneca PLC
    • AZTherapies, Inc.
    • Bausch Health Companies Inc.
    • Biogen Inc.
    • Boehringer Ingelheim International GmbH
    • Denali Therapeutics Inc.
    • Eli Lilly and Company
    • GlaxoSmithKline PLC
    • H. Lundbeck A/S
    • Johnson & Johnson Services, Inc.
    • Kyowa Kirin International plc
    • Lupin Limited
    • Merck & Co., Inc.
    • Novartis AG
    • Orion Corporation by Smiths Group plc
    • Pfizer, Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
    • Theravance Biopharma
    • UCB SA

第21章 研究人工智慧

第22章 研究统计

第23章 研究联络人

第24章 研究报导

第25章 附录

Product Code: MRR-C002B1C996F9

The Neurodegenerative Drugs Market was valued at USD 44.49 billion in 2024 and is projected to grow to USD 47.79 billion in 2025, with a CAGR of 7.66%, reaching USD 69.30 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 44.49 billion
Estimated Year [2025] USD 47.79 billion
Forecast Year [2030] USD 69.30 billion
CAGR (%) 7.66%

Unveiling the Foundations of Neurodegenerative Drug Research and Market Evolution Amidst Unprecedented Scientific and Policy Disruptions

Neurodegenerative disorders present one of the most complex challenges to modern healthcare, driven by an aging global population and multifactorial disease mechanisms. Conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis have propelled the need for novel therapeutic strategies that address both symptoms and underlying disease progression. Amid this imperative, breakthroughs in molecular biology, gene editing, and biomarker discovery are redefining the paradigms of drug development.

At the same time, regulatory landscapes are evolving to accommodate accelerated approval pathways and expanded access frameworks, creating a more flexible environment for innovators to bring therapies to patients in need. The integration of real-world evidence and digital health platforms has enhanced clinical trial design, enabling more precise patient stratification and adaptive study protocols. Collaborative models between academic institutions, biotechnology startups, and established pharmaceutical companies are further accelerating the translation of preclinical insights into clinical candidates.

Looking ahead, the focus is shifting towards holistic approaches that combine neuroprotection, immunomodulation, and synaptic support. Stakeholders are increasingly evaluating combination therapies and leveraging artificial intelligence to optimize drug discovery pipelines. This introduction sets the stage for an in-depth exploration of the transformative shifts, policy impacts, segmentation nuances, regional dynamics, and strategic imperatives that define the future of neurodegenerative drug development.

Tracing the Transformative Shifts in Neurodegenerative Therapy Landscape Fueled by Breakthrough Discoveries and Regulatory Overhauls

The neurodegenerative drug landscape is undergoing a profound metamorphosis, catalyzed by converging scientific advances and shifts in regulatory philosophy. Precision medicine initiatives have identified novel molecular targets, enabling the development of therapies that may slow or halt disease progression. Innovations in gene therapy, monoclonal antibodies, and small molecule modulators are offering unprecedented avenues for intervention. Concurrently, regulatory bodies across major markets have introduced adaptive licensing schemes and conditional approvals, recognizing the urgent unmet needs of patients affected by debilitating neurological conditions.

In parallel, technological advancements in imaging, fluid biomarkers, and omics analytics are refining diagnostic criteria and enabling earlier intervention. Digital therapeutics and remote monitoring devices are enhancing patient engagement and supporting data-driven decision making. This ecosystem of innovation has fostered strategic alliances, where biopharma companies collaborate with technology firms to co-develop integrated solutions that extend beyond traditional pharmacotherapy.

As a result, clinical trial paradigms are evolving towards decentralized models and master protocols, reducing time to market and improving the efficiency of patient recruitment. These transformative shifts not only accelerate access to cutting-edge treatments but also redefine competitive dynamics, compelling stakeholders to reevaluate their pipelines, partnerships, and go-to-market strategies in light of an increasingly agile and patient-centric environment.

Examining the Cumulative Effects of 2025 US Tariffs on Neurodegenerative Drug Supply Chains, Pricing Structures, and Global Competitiveness

The implementation of United States tariffs in 2025 has introduced a new layer of complexity to the neurodegenerative drug supply chain, impacting both active pharmaceutical ingredients and finished formulations. Manufacturers reliant on cross-border sourcing have encountered elevated input costs, leading to pricing pressures that reverberate throughout distribution networks. In response, companies have initiated supply chain realignment efforts, exploring alternative procurement corridors and reinforcing domestic manufacturing capabilities to mitigate tariff-driven cost escalations.

These developments have altered global competitiveness, particularly for firms exporting to or from regions with disparate tariff frameworks. Negotiations with contract manufacturing organizations and distribution partners now emphasize risk-sharing arrangements and flexible contract terms to absorb additional financial burdens. At the same time, pricing committees and reimbursement agencies are closely monitoring tariff-induced cost fluctuations, requiring more transparent cost-justification frameworks.

Looking forward, industry players are increasingly adopting dynamic pricing strategies and leveraging trade agreements to optimize cross-border operations. Collaboration with regulatory authorities and trade bodies has become essential to navigate evolving tariff schedules and to advocate for policy adjustments that recognize the critical nature of neurodegenerative therapies. This analysis highlights the cumulative impact of tariff policies on market dynamics, underscoring the need for adaptive supply chain resilience and strategic cost management.

Illuminating Critical Market Segmentation Insights That Inform Strategic Positioning Across Drug Types Classes Administration Modes and Patient Profiles

A nuanced understanding of market segmentation is essential for tailoring R&D investments and commercialization strategies within the neurodegenerative drug space. When examined by type, the distinction between branded and generic therapies reveals divergent value propositions, with innovative brand portfolios commanding premium pricing while generics offer cost-effective access. Within drug classes, cholinesterase inhibitors such as donepezil, pyridostigmine and rivastigmine play a key role in cognitive support, whereas decarboxylase inhibitors like benserazide, carbidopa and methyldopa complement dopamine agonists including apomorphine, cabergoline, pramipexole and rotigotine. Immunomodulators add another dimension by targeting disease-modifying pathways.

Mode of administration further segments the market into injectable, oral, and transdermal patch formats, influencing patient adherence and route-specific efficacy. Mechanisms of action are delineated between ion channel modulators-spanning potassium and sodium channel regulators-and synaptic modulators that address neurotransmitter dynamics. Therapeutic approaches divide into neuroprotection, preventive treatment and symptomatic relief, with neuroprotective strategies encompassing anti-inflammatory agents and antioxidants. Indication-based segmentation highlights applications in Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis-with primary progressive and relapsing-remitting subtypes-and Parkinson's disease. Patient demographics reveal distinct usage patterns across adult, geriatric and pediatric cohorts, while sales channels, whether offline through hospital and retail pharmacies or online platforms, shape distribution dynamics. Finally, end users spanning clinics, contract research organizations, hospitals and research institutes drive demand based on clinical and investigational needs.

Together, these segmentation insights empower leaders to align product development, pricing models and market entry strategies with the diverse needs of stakeholders across the value chain.

Uncovering Key Regional Dynamics Shaping Neurodegenerative Drug Adoption Patterns and Investment Priorities Across Major Geographies

Regional dynamics exert a profound influence on the trajectory of neurodegenerative drug adoption and investment. In the Americas, robust research infrastructure and significant public and private funding have accelerated the development of cutting-edge therapeutics, while established reimbursement frameworks support commercial scalability. Market participants in this region are leveraging advanced clinical trial networks and post-market surveillance programs to validate real-world outcomes and reinforce market access.

Across Europe, the Middle East and Africa, heterogeneous regulatory environments present both challenges and opportunities. Countries with streamlined approval pathways and patient access schemes foster innovation, whereas regions with constrained healthcare budgets demand tailored cost-benefit justifications. Geographic nuances in disease prevalence, healthcare spending and care delivery models further guide strategic partnerships and localized R&D initiatives.

The Asia-Pacific region is characterized by rapid urbanization, rising healthcare expenditure and expanding clinical trial capacity. A growing middle-class population and favorable policy incentives are attracting global players to establish manufacturing hubs and research centers. Local regulatory bodies are increasingly harmonizing guidelines with international standards, promoting faster market entry for novel therapies. Understanding these distinct regional landscapes enables stakeholders to optimize portfolio allocation, forge strategic alliances and adapt commercialization strategies to the unique parameters of each geography.

Highlighting Leading Industry Players Driving Innovation Partnerships and Competitive Strategies in the Neurodegenerative Drug Market

Within the neurodegenerative drug arena, certain organizations stand out for their pioneering approaches to research, development and commercialization. These industry leaders leverage cross-disciplinary collaborations, integrating academic insights with in-house R&D capabilities to accelerate candidate selection and preclinical validation. Strategic alliances with biotechnology firms and technology providers have allowed them to harness advanced analytics and artificial intelligence, optimizing trial design and patient recruitment strategies.

Furthermore, these companies are redefining the competitive landscape through targeted acquisitions and licensing agreements, expanding their pipelines to include both disease-modifying and symptomatic treatments. Their focus on specialty formulations and novel delivery systems has improved therapeutic outcomes and patient adherence. In parallel, they maintain robust portfolios of biomarkers and companion diagnostics, enabling more precise patient stratification and personalized care models.

To sustain their market leadership, these players continually strengthen their global footprint. They invest in manufacturing capacity, secure strategic partnerships for distribution, and engage proactively with regulatory agencies to navigate complex approval pathways. By combining financial resilience with scientific excellence, these companies set the benchmark for innovation, operational efficiency and commercial success in the neurodegenerative drug sector.

Formulating Actionable Strategic Recommendations for Industry Leaders to Navigate Evolving Market Landscapes and Regulatory Environments

To thrive in the dynamic field of neurodegenerative therapeutics, industry leaders must adopt a multi-faceted strategic approach. First, prioritizing investment in cutting-edge R&D initiatives, including gene therapies, biomarker-driven platforms and digital health integrations, will position organizations at the forefront of innovation. Second, diversifying supply chains by establishing regional manufacturing hubs and securing alternative sourcing agreements can mitigate the financial and operational risks associated with tariff fluctuations and geopolitical shifts.

In addition, fostering collaborative ecosystems with technology partners, academic centers and patient advocacy groups will accelerate translational research and enhance stakeholder engagement. This collaborative ethos should extend to regulatory strategy, where early dialogue with health authorities can streamline approval pathways and align clinical trial endpoints with payer expectations. Moreover, implementing patient-centric programs that support adherence, education and long-term outcomes will strengthen market access and underpin value-based care models.

Finally, organizations must refine their commercial strategies through dynamic pricing frameworks and adaptive go-to-market plans that reflect regional nuances and evolving reimbursement landscapes. By executing these recommendations, industry leaders can navigate uncertainties, capitalize on emerging opportunities and deliver meaningful therapeutic advances to patients living with neurodegenerative conditions.

Detailing a Robust Research Methodology Integrating Multidimensional Data Sources Expert Analyses and Rigorous Validation Processes

This study employs a comprehensive research methodology designed to deliver actionable insights and reliable analysis. The foundation rests on extensive secondary research, incorporating peer-reviewed journals, regulatory filings and clinical trial databases to map the current state of neurodegenerative drug development. Building on this, primary research engagements with key opinion leaders, including neurologists, pharmacologists and patient advocacy representatives, provide nuanced perspectives on therapeutic needs and adoption trends.

Quantitative analysis leverages real-world evidence and proprietary datasets, employing statistical validation techniques to ensure data integrity and reproducibility. Qualitative insights from expert interviews and roundtable discussions enrich the quantitative findings, identifying emerging themes and potential inflection points. The methodology also includes a thorough review of policy frameworks, trade agreements and tariff schedules to assess regulatory impacts on supply chains and pricing structures.

Data triangulation and scenario analysis further validate the robustness of conclusions, while peer benchmarking and portfolio mapping contextualize competitive positioning. This multi-dimensional approach ensures that the study's conclusions are grounded in empirical evidence, expert judgment and strategic foresight, equipping stakeholders with the insights needed to make informed decisions in the neurodegenerative drug domain.

Synthesizing Core Findings and Strategic Implications to Guide Stakeholder Decisions in the Neurodegenerative Drug Domain

The synthesis of this analysis underscores the transformative trajectories reshaping neurodegenerative drug development. Scientific breakthroughs in molecular targeting and biomarker identification are complemented by regulatory innovations that accelerate patient access. At the same time, evolving tariff policies and supply chain dynamics necessitate adaptive operational strategies to maintain cost efficiency and global competitiveness.

Segmenting the market by drug type, class, administration mode, mechanism of action, therapeutic approach, indication, demographics, sales channel and end user reveals the nuanced pathways to value creation. Regionally tailored strategies highlight the importance of understanding local regulatory frameworks, reimbursement models and healthcare infrastructure. Leading industry players demonstrate the competitive advantages of strategic partnerships, pipeline diversification and technology integration.

Actionable recommendations emphasize the need for investment in advanced R&D, supply chain resilience, collaborative ecosystems, regulatory engagement and patient-centric care models. Rigorous methodological validation ensures that these insights are not only evidence-based but also forward-looking, preparing stakeholders to navigate future uncertainties. This conclusion ties together the study's core findings, offering a clear roadmap for decision-makers seeking to capitalize on the opportunities presented by the evolving landscape of neurodegenerative therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of multi-target drugs for comprehensive neurodegeneration treatment
  • 5.2. Advancements in gene therapy for treatment of inherited neurodegenerative disorders
  • 5.3. Increasing focus on repurposing existing drugs for neurodegenerative disease applications
  • 5.4. Clinical trial breakthroughs revealing efficacy of novel neurodegenerative therapies
  • 5.5. Integration of AI and machine learning in neurodegenerative drug discovery and development
  • 5.6. Expansion of small molecule drugs targeting neuroinflammation pathways
  • 5.7. Growing impact of immunotherapy approaches in neurodegenerative disease management
  • 5.8. Progress in blood-brain barrier penetration technologies for neurodegenerative drugs
  • 5.9. Emerging role of biomarkers in personalized neurodegenerative drug development
  • 5.10. Innovative drug formulations targeting protein aggregation in neurodegenerative diseases

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Neurodegenerative Drugs Market, by Type

  • 8.1. Introduction
  • 8.2. Branded
  • 8.3. Generics

9. Neurodegenerative Drugs Market, by Drug Class

  • 9.1. Introduction
  • 9.2. Cholinesterase Inhibitors
    • 9.2.1. Donepezil
    • 9.2.2. Pyridostigmine
    • 9.2.3. Rivastigmine
  • 9.3. Decarboxylase Inhibitors
    • 9.3.1. Benserazide
    • 9.3.2. Carbidopa
    • 9.3.3. Methyldopa
  • 9.4. Dopamine Agonist
    • 9.4.1. Apomorphine
    • 9.4.2. Cabergoline
    • 9.4.3. Pramipexole
    • 9.4.4. Rotigotine
  • 9.5. Immunomodulators

10. Neurodegenerative Drugs Market, by Mode Of Administration

  • 10.1. Introduction
  • 10.2. Injectable
  • 10.3. Oral
  • 10.4. Transdermal Patch

11. Neurodegenerative Drugs Market, by Mechanism Of Action

  • 11.1. Introduction
  • 11.2. Ion Channel Modulators
    • 11.2.1. Potassium Channel Modulators
    • 11.2.2. Sodium Channel Modulators
  • 11.3. Synaptic Modulators

12. Neurodegenerative Drugs Market, by Therapeutic Approach

  • 12.1. Introduction
  • 12.2. Neuroprotection
    • 12.2.1. Anti-Inflammatory Agents
    • 12.2.2. Antioxidants
  • 12.3. Preventive Treatment
  • 12.4. Symptomatic Treatment

13. Neurodegenerative Drugs Market, by Indication

  • 13.1. Introduction
  • 13.2. Alzheimer's Disease
  • 13.3. Amyotrophic Lateral Sclerosis (ALS)
  • 13.4. Multiple Sclerosis
    • 13.4.1. Primary Progressive
    • 13.4.2. Relapsing-Remitting
  • 13.5. Parkinson's Disease

14. Neurodegenerative Drugs Market, by Patient Demographics

  • 14.1. Introduction
  • 14.2. Adult
  • 14.3. Geriatric
  • 14.4. Pediatric

15. Neurodegenerative Drugs Market, by Sales Channel

  • 15.1. Introduction
  • 15.2. Offline
    • 15.2.1. Hospitals Pharmacies
    • 15.2.2. Retail Pharmacies
  • 15.3. Online

16. Neurodegenerative Drugs Market, by End User

  • 16.1. Introduction
  • 16.2. Clinics
  • 16.3. Contract Research Organizations
  • 16.4. Hospitals
  • 16.5. Research Institutes

17. Americas Neurodegenerative Drugs Market

  • 17.1. Introduction
  • 17.2. United States
  • 17.3. Canada
  • 17.4. Mexico
  • 17.5. Brazil
  • 17.6. Argentina

18. Europe, Middle East & Africa Neurodegenerative Drugs Market

  • 18.1. Introduction
  • 18.2. United Kingdom
  • 18.3. Germany
  • 18.4. France
  • 18.5. Russia
  • 18.6. Italy
  • 18.7. Spain
  • 18.8. United Arab Emirates
  • 18.9. Saudi Arabia
  • 18.10. South Africa
  • 18.11. Denmark
  • 18.12. Netherlands
  • 18.13. Qatar
  • 18.14. Finland
  • 18.15. Sweden
  • 18.16. Nigeria
  • 18.17. Egypt
  • 18.18. Turkey
  • 18.19. Israel
  • 18.20. Norway
  • 18.21. Poland
  • 18.22. Switzerland

19. Asia-Pacific Neurodegenerative Drugs Market

  • 19.1. Introduction
  • 19.2. China
  • 19.3. India
  • 19.4. Japan
  • 19.5. Australia
  • 19.6. South Korea
  • 19.7. Indonesia
  • 19.8. Thailand
  • 19.9. Philippines
  • 19.10. Malaysia
  • 19.11. Singapore
  • 19.12. Vietnam
  • 19.13. Taiwan

20. Competitive Landscape

  • 20.1. Market Share Analysis, 2024
  • 20.2. FPNV Positioning Matrix, 2024
  • 20.3. Competitive Analysis
    • 20.3.1. Abbott Laboratories
    • 20.3.2. AbbVie Inc.
    • 20.3.3. ACADIA Pharmaceuticals Inc.
    • 20.3.4. Alpha Cognition Inc.
    • 20.3.5. Amneal Pharmaceuticals, Inc.
    • 20.3.6. Aquinnah Pharmaceuticals Inc.
    • 20.3.7. Asceneuron SA
    • 20.3.8. AstraZeneca PLC
    • 20.3.9. AZTherapies, Inc.
    • 20.3.10. Bausch Health Companies Inc.
    • 20.3.11. Biogen Inc.
    • 20.3.12. Boehringer Ingelheim International GmbH
    • 20.3.13. Denali Therapeutics Inc.
    • 20.3.14. Eli Lilly and Company
    • 20.3.15. GlaxoSmithKline PLC
    • 20.3.16. H. Lundbeck A/S
    • 20.3.17. Johnson & Johnson Services, Inc.
    • 20.3.18. Kyowa Kirin International plc
    • 20.3.19. Lupin Limited
    • 20.3.20. Merck & Co., Inc.
    • 20.3.21. Novartis AG
    • 20.3.22. Orion Corporation by Smiths Group plc
    • 20.3.23. Pfizer, Inc.
    • 20.3.24. Sanofi SA
    • 20.3.25. Takeda Pharmaceutical Company Limited
    • 20.3.26. Theravance Biopharma
    • 20.3.27. UCB S.A.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix

LIST OF FIGURES

  • FIGURE 1. NEURODEGENERATIVE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2030 (%)
  • FIGURE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 26. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 29. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 30. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 31. NEURODEGENERATIVE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. NEURODEGENERATIVE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 33. NEURODEGENERATIVE DRUGS MARKET: RESEARCHAI
  • FIGURE 34. NEURODEGENERATIVE DRUGS MARKET: RESEARCHSTATISTICS
  • FIGURE 35. NEURODEGENERATIVE DRUGS MARKET: RESEARCHCONTACTS
  • FIGURE 36. NEURODEGENERATIVE DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. NEURODEGENERATIVE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GENERICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PYRIDOSTIGMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY BENSERAZIDE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CARBIDOPA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY METHYLDOPA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY APOMORPHINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CABERGOLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRAMIPEXOLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ROTIGOTINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY POTASSIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SODIUM CHANNEL MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYNAPTIC MODULATORS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SYMPTOMATIC TREATMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS (ALS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PRIMARY PROGRESSIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RELAPSING-REMITTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEURODEGENERATIVE DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 135. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 137. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 139. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 141. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 143. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 145. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS NEURODEGENERATIVE DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 165. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 168. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 169. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 170. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED STATES NEURODEGENERATIVE DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 207. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 208. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 209. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 211. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 212. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 217. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 218. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 219. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 221. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 222. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 223. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 224. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 225. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 226. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 227. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 228. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 229. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. CANADA NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 235. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 237. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 239. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 240. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 241. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 243. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 244. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 245. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 246. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 247. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 248. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 249. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 250. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 251. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 253. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 254. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 255. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 256. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 257. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 258. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 259. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 261. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 263. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 267. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 269. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 271. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 273. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 275. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 276. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 277. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 278. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 279. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 280. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 281. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 282. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 283. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 285. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 286. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2025-2030 (USD MILLION)
  • TABLE 287. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2024 (USD MILLION)
  • TABLE 288. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025-2030 (USD MILLION)
  • TABLE 289. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY SALES CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 291. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
  • TABLE 292. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
  • TABLE 293. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. BRAZIL NEURODEGENERATIVE DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 295. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
  • TABLE 299. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 300. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 301. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 302. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DECARBOXYLASE INHIBITORS, 2025-2030 (USD MILLION)
  • TABLE 303. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2018-2024 (USD MILLION)
  • TABLE 304. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY DOPAMINE AGONIST, 2025-2030 (USD MILLION)
  • TABLE 305. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 307. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 308. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2030 (USD MILLION)
  • TABLE 309. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2018-2024 (USD MILLION)
  • TABLE 310. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY ION CHANNEL MODULATORS, 2025-2030 (USD MILLION)
  • TABLE 311. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2018-2024 (USD MILLION)
  • TABLE 312. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY THERAPEUTIC APPROACH, 2025-2030 (USD MILLION)
  • TABLE 313. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2018-2024 (USD MILLION)
  • TABLE 314. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY NEUROPROTECTION, 2025-2030 (USD MILLION)
  • TABLE 315. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 317. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2024 (USD MILLION)
  • TABLE 318. ARGENTINA NEURODEGENERATIVE DRUGS MARKET SIZE, BY MULTIPLE SCLEROSIS